Alessandro Paiardini
Screening the medicines for Malaria Venture "Malaria Box" against the Plasmodium falciparum aminopeptidases, M1, M17 and M18
Paiardini, Alessandro; Bamert, Rebecca S.; Kannan-Sivaraman, Komagal; Drinkwater, Nyssa; Mistry, Shailesh N.; Scammells, Peter J.; McGowan, Sheena
Authors
Rebecca S. Bamert
Komagal Kannan-Sivaraman
Nyssa Drinkwater
Dr SHAILESH MISTRY Shailesh.Mistry@nottingham.ac.uk
ASSOCIATE PROFESSOR
Peter J. Scammells
Sheena McGowan
Abstract
Malaria is a parasitic disease that remains a global health burden. The ability of the parasite to rapidly develop resistance to therapeutics drives an urgent need for the delivery of new drugs. The Medicines for Malaria Venture have compounds known for their antimalarial ac- tivity, but not necessarily the molecular targets. In this study, we assess the ability of the “MMV 400” compounds to inhibit the activity of three metalloaminopeptidases from Plasmo- dium falciparum, PfA-M1, PfA-M17 and PfM18 AAP. We have developed a multiplex assay system to allow rapid primary screening of compounds against all three metalloaminopepti- dases, followed by detailed analysis of promising compounds. Our results show that there were no PfM18AAP inhibitors, whereas two moderate inhibitors of the neutral aminopepti- dases PfA-M1 and PfA-M17 were identified. Further investigation through structure-activity relationship studies and molecular docking suggest that these compounds are competitive inhibitors with novel binding mechanisms, acting through either non-classical zinc coordina- tion or independently of zinc binding altogether. Although it is unlikely that inhibition of PfA- M1 and/or PfA-M17 is the primary mechanism responsible for the antiplasmodial activity re- ported for these compounds, their detailed characterization, as presented in this work, pave the way for their further optimization as a novel class of dual PfA-M1/PfA-M17 inhibitors uti- lising non-classical zinc binding groups.
Citation
Paiardini, A., Bamert, R. S., Kannan-Sivaraman, K., Drinkwater, N., Mistry, S. N., Scammells, P. J., & McGowan, S. (2015). Screening the medicines for Malaria Venture "Malaria Box" against the Plasmodium falciparum aminopeptidases, M1, M17 and M18. PLoS ONE, 10(2), Article e0115859. https://doi.org/10.1371/journal.pone.0115859
Journal Article Type | Article |
---|---|
Acceptance Date | Dec 2, 2014 |
Publication Date | Feb 20, 2015 |
Deposit Date | Sep 29, 2015 |
Publicly Available Date | Sep 29, 2015 |
Journal | PLoS ONE |
Electronic ISSN | 1932-6203 |
Publisher | Public Library of Science |
Peer Reviewed | Peer Reviewed |
Volume | 10 |
Issue | 2 |
Article Number | e0115859 |
DOI | https://doi.org/10.1371/journal.pone.0115859 |
Keywords | malaria, Plasmodium, antimalerial, aminopeptidases |
Public URL | https://nottingham-repository.worktribe.com/output/744683 |
Publisher URL | http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0115859 |
Contract Date | Sep 29, 2015 |
Files
journal.pone.0115859-2.pdf
(1.8 Mb)
PDF
Publisher Licence URL
https://creativecommons.org/licenses/by/4.0/
You might also like
Meeting report: 27th Annual GP2A Medicinal Chemistry Conference
(2019)
Journal Article
Structure-Kinetic Profiling of Haloperidol Analogues at the Human Dopamine D2 Receptor
(2019)
Journal Article
Downloadable Citations
About Repository@Nottingham
Administrator e-mail: discovery-access-systems@nottingham.ac.uk
This application uses the following open-source libraries:
SheetJS Community Edition
Apache License Version 2.0 (http://www.apache.org/licenses/)
PDF.js
Apache License Version 2.0 (http://www.apache.org/licenses/)
Font Awesome
SIL OFL 1.1 (http://scripts.sil.org/OFL)
MIT License (http://opensource.org/licenses/mit-license.html)
CC BY 3.0 ( http://creativecommons.org/licenses/by/3.0/)
Powered by Worktribe © 2025
Advanced Search